Cerevel Therapeutics Holdings Inc's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Cerevel Therapeutics Holdings Inc (CERE) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Cerevel Therapeutics Holdings Inc vs Its Competitors
- Peer differentiation: Revenue per employee of $0.00M compares with $0.72M for the peer group (0.0x).
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
Cerevel Therapeutics Holdings Inc's Competitor Quality Breadth
Share of each group, trailing 12 months: profitable (net margin > 0), expanding (revenue growth > 0), growing faster than the industry's own median, and financially distressed (Piotroski F-Score of 2 or below).
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Cerevel Therapeutics Holdings Inc | - | - | - | Yes |
| Competitors combined (111) | ||||
| High-Confidence Competitors (2) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
CERE Stock Performance relative to its Competitors
CERE Stock Performance relative to High-Confidence Competitors
5 Best-Performing Tracked Competitors, Trailing 12 Months
| # | Competitor | TTM Share Price Return | vs U.S.A. 500 |
|---|---|---|---|
| 1 | Ventyx Biosciences Inc | 282.9% | Outperformed |
| 2 | Climb Bio Inc | 282.9% | Outperformed |
| 3 | Damora Therapeutics Inc | 282.9% | Outperformed |
| 4 | Praxis Precision Medicines Inc | 282.9% | Outperformed |
| 5 | Gossamer Bio Inc | 282.9% | Outperformed |
TTM share price return and U.S.A. 500 outperformance for Cerevel Therapeutics Holdings Inc's best-performing tracked competitors requires a Commercial License.
Source: CSIMarket API, trailing 12 months.
Cerevel Therapeutics Holdings Inc's Comment on Competition and Industry Peers
We believe that we possess a number of competitive strengths that position
us to become a leading provider of seeds, traits and bioinformatics technologies,
including:
Current Commercial Products with Multiple Advanced Products in Pipeline
Our current commercial products and product pipeline contain numerous traits
and seed products with potential across multiple crops including sorghum, sugarcane
and corn, among others. Moreover, we are focused on crops and traits outside
the primary market areas of major international agrochemical and agricultural
biotechnology corporations.
Leading Platform with Full Agricultural Biotech Seed Company Capabilities
We are an agricultural biotechnology company that uses biotechnology, advanced
plant breeding and genomic technologies to create high value traits and seeds
to produce agricultural crops. Our integrated technology platform delivers a
combination of valuable genetic assets and competencies in genomics and gene
mapping, biotechnology and bioinformatics. Our iCODE technology enables high
throughput genetic testing that can speed up the trait development process.
In addition to possessing the research and development capabilities necessary
to generate new product candidates, we are vertically integrated, which gives
us the ability to bring agricultural biotechnology products to market in select
crops.
Extensive Intellectual Property Portfolio of High Value Traits and Germplasm
We have an extensive intellectual property portfolio of both field-validated
high value traits and germplasm, which includes thousands of specimens and breeding
lines, as well as multiple pools of regionally adapted germplasm spanning multiple
climates. We have extensive filings around unique combinations of gene promotors
and protein coding sequences. Having both germplasm and field-validated trait
portfolios allows us to leverage the synergies created to facilitate innovation
in a way that is not possible with germplasm or traits alone. In our focus geographies,
we believe that we have a significant advantage over new entrants who would
need several generations of germplasm development and/or access to biotech traits
to achieve performance equivalent to our current product portfolio and pipeline.
Multiple Out-Licensing Opportunities
Our biotech traits and core technology platforms provide multiple opportunities
for exclusive or non-exclusive out-licensing, by crop and/or geography and market.
Traits developed through biotechnology, also known as genetic engineering, can
be added to multiple crops with similar effect in most cases. Our strategy is
to focus on genes that have shown large, step increases in performance and whose
benefits are largely maintained across multiple species.
Positioned to Capitalize on Growth of Large End Markets
Our biotechnology platform, which has proven to increase biomass productivity,
raise quality, reduce crop inputs and improve cultivation on marginal land,
has broad application across multiple end markets and crops. Faced with increasing
demand and limited supply in addition to stresses from climate variability and
competition for water resources, growers are seeking to improve crop productivity
through a number of technologies. Agricultural biotechnology has and will continue
to represent a significant source of innovation for increasing crop yields through
improving performance of seeds.
Validated, Robust Bioinformatics Platform
We have established our Persephone bioinformatics software as a preeminent platform
for storing, organizing, accessing and visualizing genetic information, and
have displaced incumbent solutions at major life science companies. The software
includes a number of proprietary data management optimizations to quickly access
and visualize very large datasets. This speed enables more dynamic visualizations,
intuitive discovery and greater insights into genetic information. We believe
that our direct experience using Persephone internally and our ability to continually
develop and launch new versions with additional features and functions will
enable us to further establish our market position in the plant sciences and
expand into new markets, such as biomedical research and diagnostics.
Attractive Business Model
Seed businesses traditionally incur significant research and development expenditures
and have long product development time lines, but benefit from a combination
of high gross margins, low capital expenditure requirements and intellectual
property protection. Once developed, seeds require little physical infrastructure
or production cost to be replicated for sale. Seeds are typically priced, however,
based on a share of the value created to the customer as opposed to their cost
of production. In general, seed costs to growers are a relatively small percentage
of their total production cost, but the performance of those seeds is critical
to the growers’ economics. We believe we can position our business to
take advantage of low production costs relative to the high value of our products
to our customers.
Management Team with Significant Industry Experience
Our management team includes leading scientists and industry experts who have
extensive experience in the field of agricultural biotechnology and possess
a deep understanding of a variety of agricultural and biotechnology businesses,
including the seed industry.
The seed, agricultural biotechnology and genomics industries are rapidly evolving
and new competitors with competing technologies and products are regularly entering
the market. We expect to compete with other providers of seed and vegetative
propagation materials in the market for our crops as well as other developers
of biotech traits, genetic technologies and bioinformatics software. Based on
our experience with customers, we believe the primary competitive factors in
the seed industry are yield, product quality, performance, scale, price, reliable
supply and sustainability. We believe that the competitive factors affecting
the market for our Persephone software include product functionality and features,
performance, price, ease of product implementation and quality of customer support
services. We believe that our products and services currently compete favorably
with respect to such factors. However, we may not be able to maintain our competitive
position against current and potential competitors.
In the seed industry, our principal competitors may include major international
agrochemical and agricultural biotechnology corporations, such as Advanta India
Limited, The Dow Chemical Company, Monsanto Company, Pioneer Hi-Bred (DuPont),
KWS Saat AG and Syngenta AG, all of which have substantially greater resources
to dedicate to research and development, production or marketing than we have
and some of which are selling competitive products in our markets. We also face
direct competition from other seed companies, such as Chromatin, Inc., S&W
Seed Company and Winfield Solutions LLC, a subsidiary of Land O’ Lakes,
as well as biotechnology companies, and from academic and government research
institutions. In the genomics and bioinformatics market, we face direct competition
from academic and government-funded research institutions as well as commercial
software developers. In addition, well established companies, such as Illumina,
Inc., F.Hoffmann-La Roche Ltd. and Google Inc., may expand the scope of their
current analytical software and services to include visualization and exploration
functions and features similar to Persephone. We are unable to predict what
effect evolution of these industries and potential new entrants may have on
price, selling strategies, intellectual property or our competitive position.
Publicly Traded Peers of Cerevel Therapeutics Holdings Inc
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
| Cerevel Therapeutics Holdings Inc | 8,165.22 | 0.00 |
| Abbvie Inc | 463,275.89 | 64,386.00 |
| Vertex Pharmaceuticals Inc | 133,421.11 | 12,587.20 |
| Hca Healthcare Inc | 96,721.47 | 76,388.00 |
| Archer daniels midland Co | 38,499.30 | 82,099.00 |
| Biogen Inc | 33,520.59 | 9,937.40 |
| SUBTOTAL | 1,042,802.13 | 404,440.65 |
Sign in to see all competitors of Cerevel Therapeutics Holdings Inc .
Sources: Cerevel Therapeutics Holdings Inc's official press releases and regulatory filings; CSIMarket.com's market research; and the financial filings and press releases of the other companies cited.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Cerevel Therapeutics Holdings Inc versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
Cerevel Therapeutics Holdings Inc's Competitors Named by the Company
Competitive relationships identified from SEC filings and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| Sage Therapeutics Inc | Named by the company | 85% |
| KWS Saat AG | Named by the company | 85% |
| Google Inc | Named by the company | 85% |
| The Dow Chemical Company | Named by the company | 85% |
| Winfield Solutions LLC | Named by the company | 85% |
| Full Agricultural Biotech Seed Company | Named by the company | 85% |
| Syngenta AG | Named by the company | 85% |
| Current Commercial Products | Named by the company | 85% |
| Monsanto Company | Named by the company | 85% |
| F.Hoffmann-La Roche Ltd | Named by the company | 85% |
| Advanta India Limited | Named by the company | 85% |
| S&W Seed Company | Named by the company | 85% |
| Multiple Advanced Products | Named by the company | 85% |
| Avenue Therapeutics Inc | Named by the company | 85% |
| Praxis Precision Medicines Inc | Named by the company | 85% |
| Biogen Inc | Named by the company | 85% |
| Vertex Pharmaceuticals Inc | Named by the company | 85% |
| Theravance Biopharma inc | Named by the company | 85% |
| Abbvie Inc | Named by the company | 85% |
| Karuna Therapeutics Inc | Named by the company | 85% |
| Aptinyx Inc | Named by the company | 85% |
Filing basis, confidence, active dates and source counts for Cerevel Therapeutics Holdings Inc's named competitors require a Commercial License.
Methodology: relationships are extracted from SEC filings (named-competitor disclosures) and corroborating sources. Named by the company = explicitly disclosed as a competitor; Inferred = derived from corroborating signals. Confidence reflects evidence strength.
Cerevel Therapeutics Holdings Inc's Business Segment Mix vs Peers
Revenue by operating segment or division, as named and reported by each company. Segment names are the filer's own and are not standardized across companies. Do not assume a same-named or similarly-named segment is defined identically between two companies. Shares are of each company's own total revenue and are not required to sum to 100% (intersegment revenue, unallocated items).| Company | Largest Segment |
|---|---|
| Vertex Pharmaceuticals Inc | Pharmaceuticals 100.00 % |
| Hca Healthcare Inc | American Group 34.90 % |
| Archer daniels midland Co | Ag Services and Oilseeds 76.86 % |
| Biogen Inc | Reportable 100.00 % |
| Dupont De Nemours Inc | Diversified Industrials 52.94 % |
Source: operating segment revenue as reported in each company's SEC filings (10-K/10-Q), via the CSIMarket API, leaf-level reportable segments only (parent roll-up segments are excluded where sub-segments are separately disclosed).
Sign in to see all peers for Cerevel Therapeutics Holdings Inc .
Cerevel Therapeutics Holdings Inc's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| Cerevel Therapeutics Holdings Inc | 8,165 | 0 | -1,771,031 |
| Abbvie Inc | 463,276 | 1,129,579 | 110,807 |
| Vertex Pharmaceuticals Inc | 133,421 | 31,079,506 | 10,877,037 |
| Hca Healthcare Inc | 96,721 | 238,713 | 24,419 |
| Archer daniels midland Co | 38,499 | 1,978,480 | 42,872 |
| Biogen Inc | 33,521 | 1,324,987 | 182,920 |
| PEERS TOTAL | 1,034,637 | 718,033 | 26,204 |
Sign in to see all peers for Cerevel Therapeutics Holdings Inc .
Cerevel Therapeutics Holdings Inc's Geographic Revenue Exposure vs Peers
Revenue by country/region as reported in each company's most recent filing. Disclosure granularity varies by filer (some report by country, others by broad region) and is shown as disclosed.| Company | Largest Market |
|---|---|
| Vertex Pharmaceuticals Inc | United States 61.68 % |
| Horizon Therapeutics Public Limited Company | United States 97.76 % |
| Dupont De Nemours Inc | United States 44.47 % |
| Jazz Pharmaceuticals Plc | United States 89.79 % |
| Mosaic Co | United States 39.43 % |
Source: revenue geography as reported in each company's SEC filings (10-K/10-Q), via the CSIMarket API. Percentages are of that company's own total consolidated revenue for its most recent reported period.
Sign in to see all peers for Cerevel Therapeutics Holdings Inc .
Cerevel Therapeutics Holdings Inc's Valuation vs Competitive Position
Valuation multiples vs the Major Pharmaceutical Preparations industry average (341 companies, excluding loss-making/negative-equity outliers), alongside returns on capital for context on whether a premium or discount lines up with measurably stronger or weaker returns. See the full Major Pharmaceutical Preparations industry valuation benchmarks.| Metric | Company | Industry Average | Difference |
|---|---|---|---|
| P/E | - | 25.5x | - |
| EV / EBITDA | - | 17.3x | - |
| P/B | 16.4x | 4.5x | +11.8x |
| Return on Equity | -98.94 % | industry aggregate | -108.60 % |
| Return on Invested Capital | -33.53 % | -2.97 % (avg) | -30.56 % |
Source: CSIMarket API, trailing 12 months. A valuation premium or discount is not, by itself, a judgment of over- or under-valuation. Compare it against the return and growth context shown elsewhere on this page.
Cerevel Therapeutics Holdings Inc's Multi-Year Financial Trajectory
Fiscal-year revenue growth, operating margin, return on invested capital and P/E, as reported in SEC filings.| Metric | 2013 | 2015 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Revenue Growth | -27.72 % | 59.82 % | -100.00 % | - | - | - |
| Operating Margin | -838.84 % | -797.06 % | - | - | - | - |
| Return on Invested Capital | -46.17 % | -168.90 % | -72.94 % | -22.42 % | -27.97 % | -32.42 % |
| P/E | - | - | - | - | - | - |
Source: CSIMarket API, fiscal-year figures. P/E is this company's own historical ratio at each fiscal year end and can swing sharply around an earnings trough: that is real, not a data error.
Cerevel Therapeutics Holdings Inc's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
No rule matched.
Weaknesses
- Return on equity 108.6 points below the industry aggregate.
- Piotroski F-Score of 2 or below, the standard financial-distress signal.
Opportunities
- A meaningful share of tracked competitors (45.20 %) show financial-distress signals, a possible opening to gain share.
Threats
- Tracked peer group's revenue run-rate is broadly decelerating (-5.3% annualized).
Methodology: mechanical, rule-based SWOT. Each bullet reuses a figure already sourced and cited elsewhere on this page; nothing here is generated narrative or independent analyst judgment.
Cerevel Therapeutics Holdings Inc's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| Cerevel Therapeutics Holdings Inc | 3.33 | 10.31 | 0.91 |
| Abbvie Inc | 0.16 | 0.75 | - |
| Vertex Pharmaceuticals Inc | 1.34 | 2.85 | - |
| Hca Healthcare Inc | 0.06 | 0.90 | - |
| Archer daniels midland Co | 0.47 | 1.36 | 0.36 |
| Biogen Inc | - | 2.74 | 0.35 |
Sign in to see all peers for Cerevel Therapeutics Holdings Inc .
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
Cerevel Therapeutics Holdings Inc's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| Cerevel Therapeutics Holdings Inc | Q1 2024 | - | - |
| Abbvie Inc | Q2 2026 | +10.2 % | +284.3 % |
| Vertex Pharmaceuticals Inc | Q2 2026 | +12.5 % | +6.5 % |
| Hca Healthcare Inc | Q1 2026 | +4.3 % | +1.8 % |
| Archer daniels midland Co | Q2 2026 | +7.2 % | +320.3 % |
| Biogen Inc | Q1 2026 | +1.9 % | +32.8 % |
| PEERS TOTAL | +7.0 % | +112.5 % |
Sign in to see all peers for Cerevel Therapeutics Holdings Inc .
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
Cerevel Therapeutics Holdings Inc's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| Cerevel Therapeutics Holdings Inc | Q1 2024 | - | -19.3 % |
| Abbvie Inc | Q2 2026 | -1.3 % | +19.7 % |
| Vertex Pharmaceuticals Inc | Q2 2026 | +20.0 % | -23.0 % |
| Hca Healthcare Inc | Q1 2026 | - | +12.9 % |
| Archer daniels midland Co | Q2 2026 | +4.8 % | -10.8 % |
| Biogen Inc | Q1 2026 | +5.0 % | +8.7 % |
Sign in to see all peers for Cerevel Therapeutics Holdings Inc .
Cerevel Therapeutics Holdings Inc's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| Cerevel Therapeutics Holdings Inc | - | - | - |
| Abbvie Inc | 4.68% | 9.11% | - |
| Vertex Pharmaceuticals Inc | 16.88% | 19.97% | 23.31% |
| Hca Healthcare Inc | 12.94% | 18.54% | - |
| Archer daniels midland Co | 3.33% | 5.61% | 7.77% |
| Biogen Inc | 4.71% | 5.23% | 7.54% |
Sign in to see all peers for Cerevel Therapeutics Holdings Inc .
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
Cerevel Therapeutics Holdings Inc's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| Cerevel Therapeutics Holdings Inc | - | - |
| Abbvie Inc | 73.90 | 7.20 |
| Vertex Pharmaceuticals Inc | 30.48 | 10.60 |
| Hca Healthcare Inc | 14.83 | 1.27 |
| Archer daniels midland Co | 21.76 | 0.47 |
| Biogen Inc | 24.23 | 3.37 |
| PEERS AVERAGE | 72.93 | 2.58 |
Sign in to see all peers for Cerevel Therapeutics Holdings Inc .
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.
